OR WAIT 15 SECS
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.
Avantor announced on June 30, 2020 that it has expanded its Bridgewater, NJ innovation center to support bioprocessing capabilities for protein science, monoclonal antibodies (mAbs), and cell and gene therapy.
The site can now offer customized product and bioprocess development and custom cell and gene therapy reagent manufacturing, a company press release said. The company aims to minimize contamination and variability for cell and gene therapy, mAbs, and vaccines, using high purity products, single-use solutions, and small volume cGMP reagents in single-use bags.
"Innovation is about solving customer problems in a rapidly progressing biotechnology environment using contemporary technologies and thinking," said Dr. Ger Brophy, executive vice-president, Biopharma Production at Avantor, in the press release. "We collaborate with our customers from their initial discovery and development activities through scale-up and commercialization. Our solutions support industry downward cost pressure by emphasizing supply chain efficiency and improving production process performance."